Flutinasal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flutinasal

Quick Facts

Property Description
Active ingredient Fluticasone Propionate
Form Aqueous Nasal Spray Suspension
Pharmacological class Synthetic Glucocorticoid (Corticosteroid)
Common use Anti-inflammatory action in the nasal passages
Origin Synthetic fluorinated derivative

What Type of Medicine is Flutinasal?

Flutinasal is the medicinal entity known as Fluticasone Propionate Nasal Spray, classified as a powerful synthetic fluorinated corticosteroid belonging to the broader glucocorticoid pharmacological class. This distinguishes it from decongestants or oral antihistamines, positioning it as a preventative anti-inflammatory agent that addresses nasal irritation at its source. The active ingredient, Fluticasone Propionate, is a chemically manufactured derivative engineered for high topical potency. This compound is designed to achieve significant local effect while having negligible systemic absorption. This means the medication is intended to work where it is applied, rather than throughout the rest of the body. It is manufactured as a single-component product using only this compound.


Composition and Form of the Nasal Spray

The medicine is supplied as an aqueous nasal spray suspension, consisting of micronized Fluticasone Propionate powder dispersed evenly in a purified water base. The form is designed as a metered-dose spray to ensure the consistent application of the medication to the nasal lining. The intranasal route of administration ensures that the medication is optimized for absorption and action specifically within the nose, differentiating it from inhaler devices intended for the deeper respiratory tract. This focused delivery makes it useful for localized inflammation.


What is the General Purpose of Flutinasal?

The general purpose of Flutinasal is to provide localized relief by performing its primary function: sustained anti-inflammatory activity. It achieves this by acting as a glucocorticoid receptor agonist in the nasal cells, which suppresses the complex cascade of immune responses that release chemical substances like histamine and cytokines. This mechanism diminishes the internal inflammation and associated fluid buildup (edema) in the nose. The core benefit is a targeted reduction in the underlying inflammatory response, promoting clearer nasal passages.

What side effects are possible with Flutinasal?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential side effects of Flutinasal (Fluticasone Propionate Nasal Spray) based on their frequency and the system-organ class affected. The safety profile is characterized by localized effects at the site of administration and the potential for systemic corticosteroid effects upon long-term, high-dose use.

Frequency-Classified Adverse Reactions

Classification Documented Reactions
Very Common Epistaxis (Nosebleeds)
Common Headache, Nasal dryness, Nasal irritation, Throat dryness/irritation, Unpleasant taste or smell
Very Rare Hypersensitivity reactions (e.g., Anaphylaxis, Angioedema), Glaucoma, Cataracts, Nasal septal perforation

These reactions are grouped into categories such as Respiratory, Thoracic and Mediastinal Disorders (e.g., epistaxis, nasal irritation), Nervous System Disorders (headache, unpleasant taste), and Immune System Disorders (hypersensitivity).

Serious Adverse Reactions and Safety Considerations

The label documents serious adverse reactions classified as very rare, including Anaphylaxis and Angioedema. The potential for Systemic Corticosteroid Effects such as Adrenal Suppression is a regulatory concern, which is explicitly linked to very high dosages or extended periods of treatment. For long-term exposure, the development of Glaucoma or Cataracts is associated with the corticosteroid class, warranting specific observation.

Regulatory safety statements also address specific patient groups. For the pediatric population, growth monitoring may be advised during prolonged use due to the potential for growth retardation. For patients with severe hepatic impairment, the clearance of Fluticasone Propionate may be reduced, which can potentially increase systemic exposure.

Overdose and Emergency Response

Overdose Risk and When to Seek Help

The primary concern related to using this nasal spray at doses higher than recommended or for prolonged periods is the potential for systemic corticosteroid effects. Acute overdose (using too much at one time) is generally not expected to cause life-threatening symptoms, according to regulatory information.

Overdose-Related Symptoms
Chronic Overuse: Hypercorticism (symptoms of excess cortisol) and adrenal suppression (Hypothalamic-Pituitary-Adrenal axis suppression)
Long-Term Risk: Development or worsening of ocular conditions like glaucoma or cataracts.
Signs of Adrenal Suppression: Unusual tiredness, weakness, nausea, vomiting, dizziness, or fainting.

If you believe a very large amount has been swallowed, or if the individual has collapsed or is not breathing, call emergency services (such as 911) immediately. For advice regarding accidental ingestion, contact a Poison Control Center (e.g., 1-800-222-1222).

If you experience signs of hypercorticism or adrenal suppression, contact your healthcare provider. The drug may need to be discontinued slowly under medical guidance. Any change in vision, eye discomfort, or blurred vision should prompt a consultation with your doctor for evaluation of potential ocular effects.

Therapeutic Uses of Flutinasal

Flutinasal is applied in addressing symptoms associated with inflammatory or irritative processes in recurrent nasal conditions. It provides localized support that helps ease the overall symptom load. The medication is used to help relieve symptoms across several therapeutic domains.

This steroid nasal spray is commonly used across conditions characterized by periods of heightened symptoms, such as seasonal hay fever, perennial rhinitis, and Chronic Rhinosinusitis. It is relevant for managing symptom clusters including nasal congestion, rhinorrhea (runny nose), and sneezing. It offers symptomatic relief that contributes to easing distress during symptomatic periods caused by triggers like pollen, dust mites, and pet dander.

Flutinasal is utilized in settings where supportive symptom management is appropriate, as it is relevant for managing symptoms that interfere with daily comfort.

It is used for managing symptoms over extended periods, especially when structural changes like Nasal Polyps contribute to persistent obstruction and discomfort. By reducing the underlying inflammation, Flutinasal contributes to easing symptoms that interfere with daily functioning, such as supporting general well-being during symptomatic phases.

Quick Fact: Relief for Congestion
The medication helps address nasal congestion, which is related to inflammatory states within the nasal lining, which assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

This section explains the population-eligibility and non-eligibility rules for Flutinasal (Fluticasone Propionate Nasal Spray), as documented in official government regulatory sources such as the FDA and EMA.

Eligibility Scope

Classification Status Requirement
Use Allowed Adults & Adolescents Generally 12 years of age and older (some regulations define adults as 18+)
Children 4 years of age and older (use not established below this age)
Contraindicated Prohibited Patients with known hypersensitivity to Fluticasone Propionate or any ingredient in the spray

Eligibility-Related Restrictions

Restricted/Conditional Use is required for certain populations and clinical states:

  • Nasal Trauma: Use must be avoided until complete healing has occurred if the patient has recent nasal ulcers, surgery, or trauma.
  • Infections: Caution is necessary in patients with existing tuberculosis, untreated fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex.
  • Organ Function: Severe hepatic impairment requires caution and monitoring for systemic effects. Renal impairment typically requires no dose adjustment.
  • Pregnancy/Lactation: Use is restricted to cases where the potential benefit is judged to outweigh the potential risk to the fetus or infant, due to limited human data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Flutinasal (Fluticasone Propionate Nasal Spray) is defined by pharmacokinetic patterns involving its metabolic clearance. Fluticasone Propionate is a substrate of the Cytochrome P450 3A4 (CYP3A4) enzyme, which mediates its extensive first-pass metabolism. Co-administering potent inhibitors of this enzyme reduces the drug's clearance, resulting in significantly increased plasma concentrations and a heightened risk of systemic corticosteroid effects, such as adrenal suppression.

Formal Combination Restrictions

The most critical restrictions, based on official regulatory documentation, are for highly potent CYP3A4 inhibitors:

Interacting Substance Regulatory Classification Exposure Outcome
Ritonavir Not Recommended/Contraindicated Documented several hundred-fold increase in systemic exposure.
Cobicistat-containing products Avoidance Advised Expected high risk of systemic corticosteroid side-effects.

Substances Requiring Caution

Other potent CYP3A4 inhibitors, such as Ketoconazole, are documented to cause a minor increase in Flutinasal systemic exposure. Official cautions apply to co-administration, particularly if the use is prolonged. The regulatory labeling does not specify mandatory timing separation rules (e.g., "administer X hours apart") and does not explicitly document interactions with food, alcohol, or common herbal products.

Mechanism of Action

Flutinasal is a synthetic glucocorticoid that functions as an agonist of the glucocorticoid receptor (GR), a ligand-activated transcription factor located in the cytoplasm of target cells, including mast cells, eosinophils, and lymphocytes.

Upon entry into the cell, the active compound binds to the GR. This ligand-receptor complex then translocates to the cell nucleus, where it modifies gene expression via two primary mechanisms: transactivation and transrepression.

Through transrepression, the complex directly inhibits the activity of pro-inflammatory transcription factors, such as NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) and AP-1 (Activator Protein 1). This interference downregulates the synthesis of numerous pro-inflammatory mediators, including cytokines (e.g., interleukins, interferons), chemokines, eicosanoids, and key enzymes like cyclooxygenase (COX-2) and phospholipase A2. The overall result of this cascade is a broad modulation of the local inflammatory response by decreasing the cellular production and release of substances that promote tissue reaction.

Dosage and Administration Information

How to Use Flutinasal: Administration Guidelines

Flutinasal (Fluticasone Propionate/Furoate) is administered exclusively via the intranasal route using a metered-dose nasal spray pump or drops. Adherence to the prescribed regimen and technique is essential for correct use.

Dosing and Frequency

Population Starting/Usual Daily Dose Maximum Daily Dose
Adults & Adolescents (ge 12 years) Propionate: 2 sprays (100 mcg) per nostril once daily (Total 200 mcg) Propionate: 200 mcg/day
Furoate: 2 sprays (55 mcg) per nostril once daily (Total 110 mcg) Furoate: 110 mcg/day
Children (4–11 years) 1 spray (50 mcg or 27.5 mcg) per nostril once daily (Total 100 mcg or 55 mcg) Propionate: 200 mcg/day; Furoate: 110 mcg/day

Preparation and Technique

  1. Preparation: The spray device must be shaken gently before each use. The device must be primed by releasing a specified number of sprays into the air before the first use, or if it has not been used for a defined period (re-priming).
  2. Administration: Gently blow the nose to clear nostrils. Close one nostril, insert the nozzle into the other, and while breathing in gently through the nose, press the pump to release the spray. Repeat for the second spray (if directed), then repeat the process in the opposite nostril.
  3. Missed Dose: If a dose is missed, the regular dose should be used the next day. Do not use a double dose to make up for the missed one.

Duration and Restrictions

Continuous use should be at regular intervals for effectiveness. Adult self-treatment should not exceed six months, and use in children (age 4–11) should not exceed two months per year unless directed by a healthcare provider. An adult must supervise use in children. The device must be discarded after the maximum labeled number of actuations is reached.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flutinasal

Evidence for Allergic Rhinitis (Seasonal and Perennial)

Flutinasal was studied for conditions characterized by fluctuating or episodic manifestations, specifically Seasonal Allergic Rhinitis (hay fever) and Perennial Allergic Rhinitis. The main evidence base consists of numerous Randomized Controlled Trials (RCTs), where participants were assigned to the nasal spray group or the placebo group over defined time intervals. These studies were used in research exploring how symptoms change over time.

Research examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. The studies monitored measures such as the Total Nasal Symptom Score (TNSS), a composite score monitoring changes in outcomes related to physical discomfort, such as nasal congestion, sneezing, itching, and runny nose. Trials also explored outcomes related to the eyes, using Ocular Symptom Scores (TOSS). Findings describe patterns observed in studies that explored symptom changes compared to placebo.

The follow-up durations were typically limited in these initial efficacy studies, often lasting only two to four weeks. While these short-term studies contribute to the broader evidence landscape, long-term effects over extended periods, like entire allergy seasons or multiple years, are not fully established.


Studies for Chronic Rhinosinusitis and Nasal Polyps

Research has explored the use of Flutinasal in conditions characterized by persistent, long-term inflammation, such as Chronic Rhinosinusitis and Nasal Polyps. The research here also used RCTs, but these studies often featured longer observation periods than those used for seasonal allergies.

Studies explored changes in outcomes linked to inflammatory or irritative states deep within the nasal passages. The primary measures included assessing changes in the size or grade of nasal polyps as assessed by medical examination. Findings describe patterns related to changes measured during the study period in both polyp size and patient-reported symptoms.

Evidence quality varies across studies focusing on this chronic setting, and the sample sizes were limited in some pivotal trials. Specifically, comparative evidence is lacking to explore any differences in observed patterns between this medication and other available intranasal steroids when used specifically for chronic rhinosinusitis.


Identifying the Research Gaps and Uncertainties

The most significant gap is the lack of comprehensive long-term outcomes data in many studies, which means long-term effects are not fully established and certainty remains low.

Furthermore, comparative evidence is lacking for many head-to-head comparisons against all competing products, and subgroup findings are uncertain. The available data for certain groups, such as people with complex or multi-faceted comorbidities, remain insufficient. The studies contribute to the broader evidence landscape, but evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Fluticasone Propionate Nasal Spray, USP, 50 MCG - DailyMed (Authoritative Drug Label)
  2. Long-term study of fluticasone propionate aqueous nasal spray in acute and maintenance therapy of nasal polyposis (Long-term data/Durability)

Frequently Asked Questions (FAQ)

Common questions about Flutinasal (FAQ)

Q: How quickly does Flutinasal start working after the first use?

A: Official product information suggests that relief of symptoms may start to be noticed as early as 8 to 12 hours after the first administration. However, the full, greatest effect of the medication, which involves reducing inflammation, is generally achieved only after several days of continuous, regular use.

Q: Does Flutinasal interact with common pain relievers like ibuprofen or paracetamol?

A: Official drug labels primarily warn about interactions with strong inhibitors of the CYP3A4 enzyme, such as certain antifungal or antiviral medicines. Since these common pain relievers are generally not classified as strong CYP3A4 inhibitors, they are typically not cited as major interacting drugs in the same way as strong inhibitors.

Q: Will Flutinasal make me feel drowsy or affect my ability to drive?

A: Drowsiness or somnolence is not listed as a common side effect in regulatory documents. Adverse reactions are mostly localized to the nose. While rare systemic effects like dizziness have been reported in post-marketing data, Flutinasal is not typically associated with the sedative effects seen with some other allergy medications.

Q: Are there any specific foods or drinks that interact with Flutinasal?

A: Official regulatory advice recommends avoiding grapefruit juice. Regulatory documents advise avoiding grapefruit juice because it can affect the way the medication is processed by the body, potentially increasing systemic exposure.

Q: Can Flutinasal help with ear pressure or sinus headaches, or just nasal symptoms?

A: Flutinasal is indicated for the management of rhinitis symptoms, including congestion and chronic inflammation in the nasal passages and sinuses. It is thought that by reducing nasal inflammation and congestion, the medication may contribute to the relief of symptoms such as associated pressure or headaches.

Q: Is there a generic version of Flutinasal available?

A: Yes, Fluticasone Propionate Nasal Spray is the generic name of the active ingredient. Generic versions containing this compound are widely available from various manufacturers.

Q: Does Flutinasal treat the cause of allergies or just the symptoms?

A: Flutinasal is a corticosteroid that blocks the release of certain natural substances that cause inflammation. Studies and official information confirm that it effectively controls and relieves symptoms of rhinitis, but it does not cure the underlying allergy or condition.

Q: Can Flutinasal be used for non-allergy related congestion?

A: Yes, Fluticasone Propionate Nasal Spray is officially indicated for managing the nasal symptoms of perennial nonallergic rhinitis. This means the medication can be used to treat ongoing nasal issues that are not caused by an allergic trigger, in both adults and children aged 4 years and older.

Q: What's the best time of day to use Flutinasal for maximum benefit?

A: The recommended dosage is typically once daily. Official sources emphasize that the best results are generally achieved by using the medication consistently at regular intervals, which is the primary factor for maximizing benefit.

Q: How long does the relief from one dose of Flutinasal typically last?

A: Official clinical evidence indicates that the product is designed to provide sustained efficacy. When taken once a day as prescribed, the therapeutic effect is maintained over the full 24-hour dosing period.

Q: Does using Flutinasal increase the risk of getting sick or infections?

A: As with any corticosteroid, official documents note that the medication can potentially weaken the immune system. Regulatory warnings mention that for patients with existing infections or those who have been exposed to contagious diseases like chickenpox or measles, the use of this medication may require specific caution.

Q: Can teenagers use the adult version of Flutinasal?

A: Yes, official dosage guidelines confirm that adolescents aged 12 years and older follow the same starting and maximum daily dose as adults. The same product formulation is used for both adults and this age group.

Q: Is Flutinasal effective for pet allergies specifically?

A: Official indications confirm that Flutinasal is used to relieve the nasal symptoms associated with perennial allergic rhinitis. This condition includes allergic triggers such as exposure to pet dander.

Q: What should I do if the spray pump on my Flutinasal seems clogged?

A: The official instructions advise cleaning the device regularly after use. If the spray device appears to be clogged and no mist is released, the official instructions indicate that the device typically needs to be re-primed. This involves discharging a few sprays into the air until a fine mist appears again.

Q: Why is it important to aim the spray away from the nasal septum?

A: Following the administration instructions is crucial. Corticosteroids can inhibit the healing process, and aiming the spray away from the nasal septum (the wall dividing the nostrils) is intended to reduce the risk of irritation or, in very rare cases, a nasal septal perforation.

Q: Can I share my Flutinasal with another person in my family?

A: No, official patient counseling information explicitly states that each bottle of Flutinasal should only be used by one person. Sharing the nasal spray may spread germs or infections.

Q: Can elderly patients use Flutinasal without special precautions?

A: Official studies have not shown unique problems in elderly patients that would prohibit use. However, it is noted that because older patients are more likely to have reduced organ function, monitoring or potential dose adjustment may be necessary in some cases.

Q: Can Flutinasal be used to help symptoms of a common cold?

A: No, nonprescription fluticasone nasal spray is not approved for and should not be used to treat symptoms of the common cold. It is indicated specifically for the symptoms of allergic and nonallergic rhinitis.

How should Flutinasal be stored and disposed of?

How to Store and Dispose of Flutinasal? — Official Regulatory Information

The following instructions are based strictly on official regulatory labeling to ensure product stability and safe handling.

Requirement Official Regulatory Statement
Storage Temperature Store at room temperature (typically 20 C to 25 C). Do not refrigerate or freeze.
Handling/Protection Keep the container tightly closed and out of excess light and moisture. Store the bottle in an upright position. Shake gently before each use.
In-Use Stability Discard the bottle after a specified number of sprays (e.g., 120) or a set time after first use (e.g., 2 months), whichever occurs first.
Disposal Keep out of the reach of children. The best method for disposal of unused or expired product is a drug take-back program. If this is unavailable, mix the medicine with an undesirable substance (like coffee grounds), seal it in a bag, and place it in household trash. Do not flush down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flutinasal found in:

A-Z Index: